Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES

NCT01077713 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01077713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01077713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2010
Completion date
July 31, 2014
Enrollment
86 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer